

ADHS/DBHS Guidelines to the RBHAs and Providers for the Required Prior Authorization Process for Risperdal Consta



RBHAs must incorporate a prior authorization process for Risperdal Consta that is consistent with these ADHS/DBHS requirements:

1. The member must have one of the following qualifying diagnoses:
 - a. Schizophreniform Disorder
 - b. Schizophrenia
 - c. Schizoaffective Disorder
 - d. Bipolar Disorder Type I
2. The member must be at least 18 years old.
3. The member must be able to tolerate at least 2mg/day of oral risperidone.
4. The member must have a documented history of poor adherence to oral risperidone and documentation that patient education and other efforts to improve adherence have been tried (e.g. pill boxes).
5. The BHMP must taper and discontinue oral risperidone within 60 days after Risperdal Consta is initiated.
6. Target symptoms must be clearly documented and tracked over time in the psychiatric progress notes and assessments.

Prior Authorization may be approved for up to one year, but requires re-authorization annually based on clinical indication and documented benefit.